Nivolumab Hepatocellular Carcinoma Trial Completes Primary Endpoint Study

The Phase 3 study (NCT03383458) investigating nivolumab in participants with hepatocellular carcinoma at high risk of recurrence after curative hepatic resection or ablation completed its primary endpoint on 2026-02-27. This milestone signifies the completion of data collection for the trial's main objective.

Background

Nivolumab is an immunotherapy drug. This specific study focuses on its potential role in preventing recurrence of hepatocellular carcinoma (HCC), a type of liver cancer, in patients who have undergone curative treatment. HCC is a significant global health concern, and recurrence after initial treatment remains a challenge for patient management.

Trial design

The Phase 3 study, identified as NCT03383458, is titled 'A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation.' This randomized trial enrolled 545 participants. The study investigated nivolumab compared to placebo in patients with hepatocellular carcinoma who were at high risk of recurrence following complete resection or complete response after local ablation. The primary objective of the study was to investigate if nivolumab would improve recurrence-free survival (RFS) compared to placebo.

What this means

The primary completion of the NCT03383458 study marks a critical step in evaluating nivolumab for the adjuvant treatment of high-risk hepatocellular carcinoma. With the primary endpoint data collection now complete, the focus will shift to data analysis and the eventual reporting of results. These findings will be important for understanding the potential of nivolumab to impact recurrence-free survival in this patient population.

Source

The information regarding the primary completion of this trial was obtained from ClinicalTrials.gov, a public database of clinical studies. The event for study NCT03383458, titled 'A Study of Nivolumab in Participants With Hepatocellular Carcinoma Who Are at High Risk of Recurrence After Curative Hepatic Resection or Ablation,' was recorded on 2026-02-27 on clinicaltrials.gov.